Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes

Jonathan I. Silverberg¹ · Jacob P. Thyssen² · Eric L. Simpson³ · Gil Yosipovitch⁴ · Sonja Ständer⁵ · Hernan Valdez⁶ · Ricardo Rojo⁷ · Pinaki Biswas⁶ · Daniela E. Myers⁸ · Claire Feeney⁹ · Marco DiBonaventura⁶

Published online: 18 August 2021
© Springer Nature Switzerland AG 2021

Correction to:
American Journal of Clinical Dermatology (2021) 22:
541–554
<https://doi.org/10.1007/s40257-021-00604-9>

Fig. 4. Impact of treatment on **a** Dermatology Life Quality Index (DLQI)^a and **b** Children's Dermatology Life Quality Index (CDLQI)^b band descriptors. ^aFor patients ≥ 18 years of age. ^bFor patients < 18 years of age.

Page 550, Fig. 4:

The legend, which previously read:

Fig. 4. Impact of treatment on **a** Dermatology Life Quality Index (DLQI)^a and **b** Children's Dermatology Life Quality Index (CDLQI)^b band descriptors. ^aFor patients ≥ 8 years of age. ^bFor patients < 18 years of age.

Should read:

The original article can be found online at <https://doi.org/10.1007/s40257-021-00604-9>.

✉ Marco DiBonaventura
marco.dibonaventura@pfizer.com

- ¹ The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
- ² Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
- ³ Oregon Health and Science University, Portland, OR, USA
- ⁴ Miami Itch Center, Miller School of Medicine, University of Miami, Miami, FL, USA
- ⁵ Center for Chronic Pruritus, University of Münster, Münster, Germany
- ⁶ Pfizer Inc., New York, NY, USA
- ⁷ Pfizer Inc., Groton, CT, USA
- ⁸ Pfizer Inc., Collegeville, PA, USA
- ⁹ Pfizer Ltd., Surrey, UK